Department of Medicine

Considerations for Third-Line Therapy for Relapsed/Refractory DLBCL

Written by Targeted Oncology | July 31, 2023

During a Targeted Oncology Case-Based Roundtable event, Brad Haverkos, associate professor of medicine at CU School of Medicine, and other participants discussed the choice of treatment options for a patient with relapsed/refractory diffuse large B-cell lymphoma who previously received R-CHOP and pola-BR.